Actinium announces submission of IND for actimab-A in Combination with CLAG-M
Actinium announced an IND application has been submitted with the FDA for Actimab-A in combination with CLAG-M for relapsed or refractory Acute Myeloid Leukemia patients. The planned Phase 1 trial will be conducted at the Medical College of Wisconsin. February 12, 2018